CD4+FOXP3+ T regulatory cells in human autoimmunity: More than a numbers game

Journal of Immunology

Volumn 187, Issue 5, 2011, Pages 2061-2066

  Long, S Alice ^a   Buckner, Jane H ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD45RA ANTIGEN; CD45RO ANTIGEN; CORTICOSTEROID; DACLIZUMAB; GLATIRAMER; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ FOXP3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE COUNT; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; T-LYMPHOCYTES, REGULATORY;

EID: 80052649553     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003224     Document Type: Short Survey

References (104)

1. Sakaguchi, S., M. Ono, R. Setoguchi, H. Yagi, S. Hori, Z. Fehervari, J. Shimizu, T. Takahashi, and T. Nomura. 2006. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212: 8-27. (Pubitemid 44116697)
2. Bacchetta, R., L. Passerini, E. Gambineri, M. Dai, S. E. Allan, L. Perroni, F. Dagna-Bricarelli, C. Sartirana, S. Matthes-Martin, A. Lawitschka, et al. 2006. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J. Clin. Invest. 116: 1713-1722.
3. Ochs, H. D., E. Gambineri, and T. R. Torgerson. 2007. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol. Res. 38: 112-121. (Pubitemid 47574902)
4. Baecher-Allan, C., J. A. Brown, G. J. Freeman, and D. A. Hafler. 2001. CD4+ CD25 high regulatory cells in human peripheral blood. J. Immunol. 167: 1245-1253. (Pubitemid 32703119)
5. Dieckmann, D., C. H. Bruett, H. Ploettner, M. B. Lutz, and G. Schuler. 2002. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J. Exp. Med. 196: 247-253. (Pubitemid 34787514)
6. Stephens, L. A., C. Mottet, D. Mason, and F. Powrie. 2001. Human CD4(+) CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur. J. Immunol. 31: 1247-1254.
7. Fontenot, J. D., and A. Y. Rudensky. 2005. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6: 331-337. (Pubitemid 41716769)
8. Brusko, T. M., C. H. Wasserfall, M. J. Clare-Salzler, D. A. Schatz, and M. A. Atkinson. 2005. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 54: 1407-1414. (Pubitemid 40586671)
9. Cao, D., V. Malmström, C. Baecher-Allan, D. Hafler, L. Klareskog, and C. Trollmo. 2003. Isolation and functional characterization of regulatory CD25 bright CD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur. J. Immunol. 33: 215-223. (Pubitemid 36157659)
10. Feger, U., C. Luther, S. Poeschel, A. Melms, E. Tolosa, and H. Wiendl. 2007. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin. Exp. Immunol. 147: 412-418. (Pubitemid 46208041)
11. Haas, J., A. Hug, A. Viehöver, B. Fritzsching, C. S. Falk, A. Filser, T. Vetter, L. Milkova, M. Korporal, B. Fritz, et al. 2005. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35: 3343-3352. (Pubitemid 41672538)
12. Lindley, S., C. M. Dayan, A. Bishop, B. O. Roep, M. Peakman, and T. I. Tree. 2005. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54: 92-99. (Pubitemid 40105099)
13. Möttönen, M., J. Heikkinen, L. Mustonen, P. Isomäki, R. Luukkainen, and O. Lassila. 2005. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin. Exp. Immunol. 140: 360-367. (Pubitemid 40559165)
14. Putheti, P., A. Pettersson, M. Soderstrom, H. Link, and Y. M. Huang. 2004. Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J. Clin. Immunol. 24: 155-161. (Pubitemid 38457229)
15. Putnam, A. L., F. Vendrame, F. Dotta, and P. A. Gottlieb. 2005. CD4+CD25high regulatory T cells in human autoimmune diabetes. J. Autoimmun. 24: 55-62. (Pubitemid 40269495)
16. Viglietta, V., C. Baecher-Allan, H. L. Weiner, and D. A. Hafler. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199: 971-979. (Pubitemid 38481088)
17. Kumar, M., N. Putzki, V. Limmroth, R. Remus, M. Lindemann, D. Knop, N. Mueller, C. Hardt, E. Kreuzfelder, and H. Grosse-Wilde. 2006. CD4+CD25+ FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J. Neuroimmunol. 180: 178-184. (Pubitemid 44767710)
18. Venken, K., N. Hellings, T. Broekmans, K. Hensen, J. L. Rummens, and P. Stinissen. 2008. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J. Immunol. 180: 6411-6420.
19. Han, G. M., N. J. O'Neil-Andersen, R. B. Zurier, and D. A. Lawrence. 2008. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell. Immunol. 253: 92-101.
20. Marwaha, A. K., S. Q. Crome, C. Panagiotopoulos, K. B. Berg, H. Qin, Q. Ouyang, L. Xu, J. J. Priatel, M. K. Levings, and R. Tan. 2010. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J. Immunol. 185: 3814-3818.
21. Gerli, R., G. Nocentini, A. Alunno, E. B. Bocci, R. Bianchini, O. Bistoni, and C. Riccardi. 2009. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun. Rev. 8: 426-430.
22. Crispin, J. C., A. Martínez, and J. Alcocer-Varela. 2003. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 21: 273-276. (Pubitemid 37410115)
23. Lee, J. H., L. C. Wang, Y. T. Lin, Y. H. Yang, D. T. Lin, and B. L. Chiang. 2006. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 117: 280-286.
24. Mellor-Pita, S., M. J. Citores, R. Castejon, P. Tutor-Ureta, M. Yebra-Bango, J. L. Andreu, and J. A. Vargas. 2006. Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 65: 553-554.
25. Miyara, M., Z. Amoura, C. Parizot, C. Badoual, K. Dorgham, S. Trad, D. Nochy, P. Debré, J. C. Piette, and G. Gorochov. 2005. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol. 175: 8392-8400. (Pubitemid 41798406)
26. Suen, J. L., H. T. Li, Y. J. Jong, B. L. Chiang, and J. H. Yen. 2009. Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology 127: 196-205.
27. Tang, Q., J. Y. Adams, C. Penaranda, K. Melli, E. Piaggio, E. Sgouroudis, C. A. Piccirillo, B. L. Salomon, and J. A. Bluestone. 2008. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28: 687-697.
28. Morgan, M. E., R. P. Sutmuller, H. J. Witteveen, L. M. Van Duivenvoorde, E. Zanelli, C. J. Melief, A. Snijders, R. Offringa, R. R. De Vries, and R. E. Toes. 2003. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum. 48: 1452-1460. (Pubitemid 36554546)
29. Ziegler, S. F. 2007. FOXP3: not just for regulatory T cells anymore. Eur. J. Immunol. 37: 21-23. (Pubitemid 46128782)
30. Thornton, A. M., P. E. Korty, D. Q. Tran, E. A. Wohlfert, P. E. Murray, Y. Belkaid, and E. M. Shevach. 2010. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184: 3433-3441.
31. Maul, J., C. Loddenkemper, P. Mundt, E. Berg, T. Giese, A. Stallmach, M. Zeitz, and R. Duchmann. 2005. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128: 1868-1878. (Pubitemid 40824698)
32. Uhlig, H. H., J. Coombes, C. Mottet, A. Izcue, C. Thompson, A. Fanger, A. Tannapfel, J. D. Fontenot, F. Ramsdell, and F. Powrie. 2006. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J. Immunol. 177: 5852-5860.
33. Zhou, X., S. L. Bailey-Bucktrout, L. T. Jeker, C. Penaranda, M. Martínez-Llordella, M. Ashby, M. Nakayama, W. Rosenthal, and J. A. Bluestone. 2009. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10: 1000-1007.
34. Banham, A. H., F. M. Powrie, and E. Suri-Payer. 2006. FOXP3+ regulatory T cells: current controversies and future perspectives. Eur. J. Immunol. 36: 2832-2836. (Pubitemid 44782555)
35. Campbell, D. J., and M. A. Koch. 2011. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat. Rev. Immunol. 11: 119-130.
36. Bluestone, J. A., and A. K. Abbas. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3: 253-257. (Pubitemid 37323210)
37. Haas, J., B. Fritzsching, P. Trübswetter, M. Korporal, L.Milkova, B. Fritz, D. Vobis, P. H. Krammer, E. Suri-Payer, and B. Wildemann. 2007. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J. Immunol. 179: 1322-1330.
38. Booth, N. J., A. J. McQuaid, T. Sobande, S. Kissane, E. Agius, S. E. Jackson, M. Salmon, F. Falciani, K. Yong, M. H. Rustin, et al. 2010. Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J. Immunol. 184: 4317-4326.
39. Miyara, M., Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taflin, T. Heike, D. Valeyre, et al. 2009. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30: 899-911.
40. Long, S. A., K. Cerosaletti, P. L. Bollyky, M. Tatum, H. Shilling, S. Zhang, Z. Y. Zhang, C. Pihoker, S. Sanda, C. Greenbaum, and J. H. Buckner. 2010. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 59: 407-415.
41. Huehn, J., J. K. Polansky, and A. Hamann. 2009. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nat. Rev. Immunol. 9: 83-89.
42. Curotto de Lafaille, M. A., and J. J. Lafaille. 2009. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30: 626-635.
43. Thompson, L. J., A. C. Valladao, and S. F. Ziegler. 2011. Cutting edge: de novo induction of functional foxp3+ regulatory CD4 T cells in response to tissue-restricted self antigen. J. Immunol. 186: 4551-4555.
44. Zheng, S. G., J. Wang, P. Wang, J. D. Gray, and D. A. Horwitz. 2007. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J. Immunol. 178: 2018-2027. (Pubitemid 46233398)
45. Long, S. A., M. R. Walker, M. Rieck, E. James, W. W. Kwok, S. Sanda, C. Pihoker, C. Greenbaum, G. T. Nepom, and J. H. Buckner. 2009. Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects. Eur. J. Immunol. 39: 612-620.
46. Schneider, A., M. Rieck, S. Sanda, C. Pihoker, C. Greenbaum, and J. H. Buckner. 2008. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 181: 7350-7355.
47. Crispín, J. C., and G. C. Tsokos. 2009. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun. Rev. 8: 190-195.
48. Humrich, J. Y., H. Morbach, R. Undeutsch, P. Enghard, S. Rosenberger, O. Weigert, L. Kloke, J. Heimann, T. Gaber, S. Brandenburg, et al. 2010. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl. Acad. Sci. USA 107: 204-209.
49. Bollyky, P. L., B. A. Falk, R. P. Wu, J. H. Buckner, T. N. Wight, and G. T. Nepom. 2009. Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells. J. Leukoc. Biol. 86: 567-572.
50. Chen, X., and J. J. Oppenheim. 2010. TNF-alpha: an activator of CD4+FoxP3+ TNFR2+ regulatory T cells. Curr. Dir. Autoimmun. 11: 119-134.
51. Oberg, H. H., T. T. Ly, S. Ussat, T. Meyer, D. Kabelitz, and D. Wesch. 2010. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J. Immunol. 184: 4733-4740.
52. Tanaka, S., S. Maeda, M. Hashimoto, C. Fujimori, Y. Ito, S. Teradaira, K. Hirota, H. Yoshitomi, T. Katakai, A. Shimizu, et al. 2010. Graded attenuation of TCR signaling elicits distinct autoimmune diseases by altering thymic T cell selection and regulatory T cell function. J. Immunol. 185: 2295-2305.
53. Vukmanovic-Stejic, M., Y. Zhang, J. E. Cook, J. M. Fletcher, A. McQuaid, J. E. Masters, M. H. Rustin, L. S. Taams, P. C. Beverley, D. C. Macallan, and A. N. Akbar. 2006. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 116: 2423-2433. (Pubitemid 44330141)
54. Gebe, J. A., B. A. Falk, K. A. Rock, S. A. Kochik, A. K. Heninger, H. Reijonen, W. W. Kwok, and G. T. Nepom. 2003. Low-avidity recognition by CD4+ T cells directed to self-antigens. Eur. J. Immunol. 33: 1409-1417. (Pubitemid 36609160)
55. Valencia, X., G. Stephens, R. Goldbach-Mansky, M. Wilson, E. M. Shevach, and P. E. Lipsky. 2006. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108: 253-261. (Pubitemid 43990636)
56. Cvetanovich, G. L., and D. A. Hafler. 2010. Human regulatory T cells in autoimmune diseases. Curr. Opin. Immunol. 22: 753-760.
57. Fritzsching, B., N. Oberle, N. Eberhardt, S. Quick, J. Haas, B. Wildemann, P. H. Krammer, and E. Suri-Payer. 2005. In contrast to effector T cells, CD4+ CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J. Immunol. 175: 32-36. (Pubitemid 40884298)
58. Fritzsching, B., M. Korporal, J. Haas, P. H. Krammer, E. Suri-Payer, and B. Wildemann. 2006. Similar sensitivity of regulatory T cells towards CD95L-mediated apoptosis in patients with multiple sclerosis and healthy individuals. J. Neurol. Sci. 251: 91-97. (Pubitemid 44792146)
59. Jailwala, P., J. Waukau, S. Glisic, S. Jana, S. Ehlenbach, M. Hessner, R. Alemzadeh, S. Matsuyama, P. Laud, X. Wang, and S. Ghosh. 2009. Apoptosis of CD4+ CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS ONE 4: e6527.
60. Liu, W., A. L. Putnam, Z. Xu-Yu, G. L. Szot, M. R. Lee, S. Zhu, P. A. Gottlieb, P. Kapranov, T. R. Gingeras, B. Fazekas de St Groth, et al. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203: 1701-1711. (Pubitemid 44036276)
61. Seddiki, N., B. Santner-Nanan, J. Martinson, J. Zaunders, S. Sasson, A. Landay, M. Solomon, W. Selby, S. I. Alexander, R. Nanan, et al. 2006. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203: 1693-1700. (Pubitemid 44036275)
62. Michel, L., L. Berthelot, S. Pettré, S. Wiertlewski, F. Lefrère, C. Braudeau, S. Brouard, J. P. Soulillou, and D. A. Laplaud. 2008. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J. Clin. Invest. 118: 3411-3419.
63. Brusko, T., C. Wasserfall, K. McGrail, R. Schatz, H. L. Viener, D. Schatz, M. Haller, J. Rockell, P. Gottlieb, M. Clare-Salzler, and M. Atkinson. 2007. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 56: 604-612. (Pubitemid 46348451)
64. Lawson, J. M., J. Tremble, C. Dayan, H. Beyan, R. D. Leslie, M. Peakman, and T. I. Tree. 2008. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154: 353-359.
65. Bynoe, M. S., and C. Viret. 2008. Foxp3+CD4+ T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol. 29: 99-102.
66. Borsellino, G., M. Kleinewietfeld, D. Di Mitri, A. Sternjak, A. Diamantini, R. Giometto, S. Höpner, D. Centonze, G. Bernardi, M. L. Dell'Acqua, et al. 2007. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110: 1225-1232. (Pubitemid 47281420)
67. Fletcher, J. M., R. Lonergan, L. Costelloe, K. Kinsella, B. Moran, C. O'Farrelly, N. Tubridy, and K. H. Mills. 2009. CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 183: 7602-7610.
68. Tree, T. I., B. O. Roep, and M. Peakman. 2006. A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann. N. Y. Acad. Sci. 1079: 9-18. (Pubitemid 44968695)
69. Astier, A. L., G. Meiffren, S. Freeman, and D. A. Hafler. 2006. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 116: 3252-3257. (Pubitemid 44878639)
70. Huan, J., N. Culbertson, L. Spencer, R. Bartholomew, G. G. Burrows, Y. K. Chou, D. Bourdette, S. F. Ziegler, H. Offner, and A. A. Vandenbark. 2005. Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 81: 45-52. (Pubitemid 41139109)
71. Valencia, X., C. Yarboro, G. Illei, and P. E. Lipsky. 2007. Deficient CD4+ CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 178: 2579-2588. (Pubitemid 46233461)
72. Venigalla, R. K., T. Tretter, S. Krienke, R. Max, V. Eckstein, N. Blank, C. Fiehn, A. D. Ho, and H. M. Lorenz. 2008. Reduced CD4+, CD25- T cell sensitivity to the suppressive function of CD4+, CD25high, CD127-/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum. 58: 2120-2130. (Pubitemid 351988104)
73. Zhang, B., X. Zhang, F. Tang, L. Zhu, and Y. Liu. 2008. Reduction of forkhead box P3 levels in CD4+CD25high T cells in patients with new-onset systemic lupus erythematosus. Clin. Exp. Immunol. 153: 182-187. (Pubitemid 351989160)
74. Vargas-Rojas, M. I., J. C. Crispín, Y. Richaud-Patin, and J. Alcocer-Varela. 2008. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 17: 289-294. (Pubitemid 351655795)
75. Yates, J., A. Whittington, P. Mitchell, R. I. Lechler, L. Lightstone, and G. Lombardi. 2008. Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis. Clin. Exp. Immunol. 153: 44-55. (Pubitemid 351809334)
76. Ehrenstein, M. R., J. G. Evans, A. Singh, S. Moore, G. Warnes, D. A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200: 277-285. (Pubitemid 39031247)
77. Flores-Borja, F., E. C. Jury, C. Mauri, and M. R. Ehrenstein. 2008. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 105: 19396-19401.
78. Walker, L. S. 2009. Regulatory T cells overturned: the effectors fight back. Immunology 126: 466-474.
79. Wohlfert, E. A., and R. B. Clark. 2007. 'Vive la Résistance!': the PI3K-Akt pathway can determine target sensitivity to regulatory T cell suppression. Trends Immunol. 28: 154-160. (Pubitemid 46467517)
80. Yang, J., M. O. Brook, M. Carvalho-Gaspar, J. Zhang, H. E. Ramon, M. H. Sayegh, K. J. Wood, L. A. Turka, and N. D. Jones. 2007. Allograft rejection mediated by memory T cells is resistant to regulation. Proc. Natl. Acad. Sci. USA 104: 19954-19959.
81. Yates, J., F. Rovis, P. Mitchell, B. Afzali, J. Y. Tsang, M. Garin, R. I. Lechler, G. Lombardi, and O. A. Garden. 2007. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int. Immunol. 19: 785-799. (Pubitemid 47073268)
82. Takeda, I., S. Ine, N. Killeen, L. C. Ndhlovu, K. Murata, S. Satomi, K. Sugamura, and N. Ishii. 2004. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J. Immunol. 172: 3580-3589. (Pubitemid 38337939)
83. Choi, B. K., J. S. Bae, E. M. Choi, W. J. Kang, S. Sakaguchi, D. S. Vinay, and B. S. Kwon. 2004. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J. Leukoc. Biol. 75: 785-791. (Pubitemid 38580058)
84. Kabelitz, D., D. Wesch, and H. H. Oberg. 2006. Regulation of regulatory T cells: role of dendritic cells and Toll-like receptors. Crit. Rev. Immunol. 26: 291-306.
85. Katz, J. B., A. J.Muller, and G. C. Prendergast. 2008. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 222: 206-221. (Pubitemid 351430372)
86. Nepom, G. T., and H. Erlich. 1991. MHC class-II molecules and autoimmunity. Annu. Rev. Immunol. 9: 493-525.
87. Baranzini, S. E. 2009. The genetics of autoimmune diseases: a networked perspective. Curr. Opin. Immunol. 21: 596-605.
88. Zenewicz, L. A., C. Abraham, R. A. Flavell, and J. H. Cho. 2010. Unraveling the genetics of autoimmunity. Cell 140: 791-797.
89. Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.
90. Hafler, D. A., A. Compston, S. Sawcer, E. S. Lander, M. J. Daly, P. L. De Jager, P. I. De Bakker, S. B. Gabriel, D. B. Mirel, A. J. Ivinson, et al International Multiple Sclerosis Genetics Consortium. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357: 851-862. (Pubitemid 47347319)
91. Harley, J. B., M. E. Alarcón-Riquelme, L. A. Criswell, C. O. Jacob, R. P. Kimberly, K. L. Moser, B. P. Tsao, T. J. Vyse, C. D. Langefeld, S. K. Nath, et alInternational Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN). 2008. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40: 204-210. (Pubitemid 351171405)
92. Lowe, C. E., J. D. Cooper, T. Brusko, N. M. Walker, D. J. Smyth, R. Bailey, K. Bourget, V. Plagnol, S. Field, M. Atkinson, et al. 2007. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. 39: 1074-1082. (Pubitemid 47340651)
93. Maier, L. M., C. E. Lowe, J. Cooper, K. Downes, D. E. Anderson, C. Severson, P. M. Clark, B. Healy, N. Walker, C. Aubin, et alInternational Multiple Sclerosis Genetics Consortium. 2009. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 5: e1000322.
94. Maier, L. M., D. E. Anderson, C. A. Severson, C. Baecher-Allan, B. Healy, D. V. Liu, K. D. Wittrup, P. L. De Jager, and D. A. Hafler. 2009. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J. Immunol. 182: 1541-1547.
95. Long, S. A., K. Cerosaletti, J. Y.Wan, J. C. Ho, M. Tatum, S.Wei, H. G. Shilling, and J. H. Buckner. 2011. An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun. 12: 116-125.
96. Vang, T., M. Congia, M. D. Macis, L. Musumeci, V. Orrú, P. Zavattari, K. Nika, L. Tautz, K. Taskén, F. Cucca, et al. 2005. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37: 1317-1319. (Pubitemid 41722185)
97. Rieck, M., A. Arechiga, S. Onengut-Gumuscu, C. Greenbaum, P. Concannon, and J. H. Buckner. 2007. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J. Immunol. 179: 4704-4710.
98. Gregersen, P. K., H. S. Lee, F. Batliwalla, and A. B. Begovich. 2006. PTPN22: setting thresholds for autoimmunity. Semin. Immunol. 18: 214-223. (Pubitemid 43903284)
99. Chistiakov, D. A., and A. P. Chistiakov. 2007. Is FCRL3 a new general autoimmunity gene? Hum. Immunol. 68: 375-383. (Pubitemid 46616981)
100. Swainson, L. A., J. E. Mold, U. D. Bajpai, and J. M. McCune. 2010. Expression of the autoimmune susceptibility gene FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell death-1. J. Immunol. 184: 3639-3647.
101. Suárez, A., P. López, J. Gómez, and C. Gutiérrez. 2006. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann. Rheum. Dis. 65: 1512-1517. (Pubitemid 44629132)
102. Zhang, L., X. Q. Yang, J. Cheng, R. S. Hui, and T. W. Gao. 2010. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clin. Immunol. 135: 108-117.
103. Venken, K., N. Hellings, M. Thewissen, V. Somers, K. Hensen, J. L. Rummens, R. Medaer, R. Hupperts, and P. Stinissen. 2008. Compromised CD4(+) CD25 (high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123: 79-89. (Pubitemid 350255996)
104. Oh, U., G. Blevins, C. Griffith, N. Richert, D. Maric, C. R. Lee, H. McFarland, and S. Jacobson. 2009. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch. Neurol. 66: 471-479.